CEBP δ/CEBPD Antibody (Rabbit mAb) [F16N9]

Application: Reactivity: Mouse, Rat, Human

Usage Information

Dilution
WB1:1000 IP1:30 IHC1:500

Application
WB, IP, IHC

Reactivity
Mouse, Rat, Human

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
28 kDa 29 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight. Post-translational modifications(e.g., phosphorylation, glycosylation); Splice variants and isoforms; Relative charge; Multimerization.

Datasheet & SDS

Biological Description

Specificity
CEBP δ/CEBPD Antibody (Rabbit mAb) [F16N9] detects endogenous levels of total CEBP δ/CEBPD protein.

Clone
F16N9

Synonym(s)
CCAAT/enhancer-binding protein delta, C/EBP delta, Nuclear factor NF-IL6-beta, NF-IL6-beta, CEBPD

Background
CEBP δ (CEBPD, C/EBPδ) is a basic leucine zipper transcription factor of the CCAAT/enhancer-binding protein family that binds CCAAT/enhancer motifs as homo- or heterodimers and modulates gene expression programs linked to differentiation, inflammation, stress responses and genomic stability across multiple tissues. The protein contains a C‑terminal bZIP domain that mediates dimerization and sequence-specific DNA binding and an N‑terminal transactivation region that recruits co-regulators, giving CEBPD the capacity to act as either a transcriptional activator or repressor depending on promoter context, partner composition and post-translational modification state. Induction of CEBPD by inflammatory cytokines such as TNFα and IL‑1β in chronically inflamed tissue leads to activation of downstream targets involved in cell-cycle control and chromosomal stability; TNFα-driven CEBPD expression upregulates Aurora kinase C (AURKC) transcription, promotes centromere abnormalities and aneuploidy, and enhances anchorage-independent growth, indicating that CEBPD can link inflammatory signaling to genomic instability through direct control of mitotic regulators. In glioma, inflammatory IL‑1β elevates CEBPD in glioma stem-like cells and CEBPD directly activates PDGFA transcription, driving spheroid formation and self-renewal and supporting a role for CEBPD as a mediator of inflammation-enhanced stemness via PDGFA–PDGFR signaling. CEBPD also participates in hypoxia adaptation and metastasis: it amplifies HIF‑1α signaling, contributes to recruitment of blood vessels and integration of hypoxic inflammation with tumor spread, and its expression in tumor and stromal compartments helps establish a tumor-promoting microenvironment with enhanced angiogenesis and extravasation. In liver cancer, CEBPD behaves predominantly as a tumor suppressor; clinical analysis in hepatocellular carcinoma shows that CEBPD downregulation correlates with poor prognosis, while CEBPD drives compartment-specific growth suppression and modulates genes involved in cell-cycle arrest and apoptosis, positioning it as a regulator of HCC progression whose loss favors aggressive disease. In mouse embryonic fibroblasts, CEBPD influences DNA damage responses and p53 pathway behavior: Cebpd knockout MEFs display higher resistance to genotoxins such as cisplatin and methyl methanesulfonate, associated with altered p53 and Erk activation, and MMS treatment induces CEBPD protein together with phospho‑Ser15 p53 and p21 without increasing p53 mRNA, suggesting that CEBPD functions downstream of p38 to modulate p53 and p21 activation and thereby apoptosis and repair signaling. CEBPD expression is sparse in many adult tissues but inducible under stress, and its diverse functions, ranging from growth arrest and differentiation to promotion of hypoxia-driven metastasis, are highly context-dependent, reflecting the impact of cell type, inflammatory milieu and interacting transcription factors on its transcriptional output.

Background

CEBP δ (CEBPD, C/EBPδ) is a basic leucine zipper transcription factor of the CCAAT/enhancer-binding protein family that binds CCAAT/enhancer motifs as homo- or heterodimers and modulates gene expression programs linked to differentiation, inflammation, stress responses and genomic stability across multiple tissues. The protein contains a C‑terminal bZIP domain that mediates dimerization and sequence-specific DNA binding and an N‑terminal transactivation region that recruits co-regulators, giving CEBPD the capacity to act as either a transcriptional activator or repressor depending on promoter context, partner composition and post-translational modification state. Induction of CEBPD by inflammatory cytokines such as TNFα and IL‑1β in chronically inflamed tissue leads to activation of downstream targets involved in cell-cycle control and chromosomal stability; TNFα-driven CEBPD expression upregulates Aurora kinase C (AURKC) transcription, promotes centromere abnormalities and aneuploidy, and enhances anchorage-independent growth, indicating that CEBPD can link inflammatory signaling to genomic instability through direct control of mitotic regulators. In glioma, inflammatory IL‑1β elevates CEBPD in glioma stem-like cells and CEBPD directly activates PDGFA transcription, driving spheroid formation and self-renewal and supporting a role for CEBPD as a mediator of inflammation-enhanced stemness via PDGFA–PDGFR signaling. CEBPD also participates in hypoxia adaptation and metastasis: it amplifies HIF‑1α signaling, contributes to recruitment of blood vessels and integration of hypoxic inflammation with tumor spread, and its expression in tumor and stromal compartments helps establish a tumor-promoting microenvironment with enhanced angiogenesis and extravasation. In liver cancer, CEBPD behaves predominantly as a tumor suppressor; clinical analysis in hepatocellular carcinoma shows that CEBPD downregulation correlates with poor prognosis, while CEBPD drives compartment-specific growth suppression and modulates genes involved in cell-cycle arrest and apoptosis, positioning it as a regulator of HCC progression whose loss favors aggressive disease. In mouse embryonic fibroblasts, CEBPD influences DNA damage responses and p53 pathway behavior: Cebpd knockout MEFs display higher resistance to genotoxins such as cisplatin and methyl methanesulfonate, associated with altered p53 and Erk activation, and MMS treatment induces CEBPD protein together with phospho‑Ser15 p53 and p21 without increasing p53 mRNA, suggesting that CEBPD functions downstream of p38 to modulate p53 and p21 activation and thereby apoptosis and repair signaling. CEBPD expression is sparse in many adult tissues but inducible under stress, and its diverse functions, ranging from growth arrest and differentiation to promotion of hypoxia-driven metastasis, are highly context-dependent, reflecting the impact of cell type, inflammatory milieu and interacting transcription factors on its transcriptional output.

References
https://pubmed.ncbi.nlm.nih.gov/21715338/ https://pubmed.ncbi.nlm.nih.gov/24155666/

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%